GR 89696 fumarate salt
CAS: 126766-32-3
Ref. 3D-BFA76632
| 5mg | A consultar | ||
| 10mg | A consultar | ||
| 25mg | A consultar | ||
| 50mg | A consultar | ||
| 100mg | A consultar |
Información del producto
- 1-Piperazinecarboxylic acid, 4-[(3,4-dichlorophenyl)acetyl]-3-(1-pyrrolidinylmethyl)-, methyl ester, (2E)-2-butenedioate (1:1)
- 1-Piperazinecarboxylic acid, 4-[(3,4-dichlorophenyl)acetyl]-3-(1-pyrrolidinylmethyl)-, methyl ester, (E)-2-butenedioate (1:1)
- 1-Piperazinecarboxylic acid, 4-[2-(3,4-dichlorophenyl)acetyl]-3-(1-pyrrolidinylmethyl)-, methyl ester, (2E)-2-butenedioate (1:1)
- Gr 89696
- Methyl 4-[(3,4-dichlorophenyl)acetyl]-3-(pyrrolidin-1-ylmethyl)piperazine-1-carboxylate (2E)-but-2-enedioate (1:1)
GR 89696 is a kappa-opioid receptor agonist that is a racemic mixture of the two enantiomers, S and R. It has high affinity for the human kappa-opioid receptor, with values of 500 nM and 100 nM for the S and R enantiomers, respectively. GR 89696 has been shown to produce antinociception in experimental animals. This effect was blocked by pretreatment with the δ-opioid antagonist naltrindole, but not by pretreatment with the κ-opioid antagonist norbinaltorphimine or the κ/δ-opioid antagonist pentazocine. The drug also inhibits rotarod performance in mice at low doses, which may be due to its sedative effect.
GR 89696 has been shown to inhibit bone cancer cell growth in vitro and in vivo without inducing significant toxicity in healthy cells. The drug also showed efficacy against
Propiedades químicas
Consulta técnica sobre: 3D-BFA76632 GR 89696 fumarate salt
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
